Venus Concept  logo
Venus Concept VERO

Quarterly report 2025-Q3
added 11-13-2025

report update icon

Venus Concept Financial Statements 2011-2026 | VERO

Annual Financial Statements Venus Concept

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.84 M 386 K 748 K 92.6 M 69.6 M 62.3 M 29.8 M 153 M - - - - - -

Shares

660 K 544 K 4.4 M 54.5 M 36.6 M 8.52 M 2.23 M 1.93 M - - - - - -

Historical Prices

2.79 0.71 0.17 1.7 1.73 4.7 6.54 69 - - - - - -

Net Income

-47 M -37.2 M -43.7 M -23 M -81.7 M -40.6 M -28.7 M -17.8 M -21.8 M -23 M - - - -

Revenue

64.8 M 76.4 M 99.5 M 106 M 78 M 110 M 22 M 21.3 M 15.6 M 17.2 M - - - -

Cost of Revenue

20.5 M 24.2 M 33.5 M 31.5 M 26.6 M 33.8 M 23.3 M 12.2 M 10.4 M 12.5 M - - - -

Gross Profit

44.3 M 52.2 M 66 M 74.1 M 51.4 M 76.7 M 9.51 M 9.15 M 5.17 M 4.72 M - - - -

Operating Income

-27.2 M -28.3 M -34.9 M -14.8 M -67.9 M -30.3 M -3.37 M -17.3 M -18.9 M -20.5 M - - - -

Interest Expense

- - - - - - -549 K -328 K -431 K 446 K - - - -

EBITDA

-23.3 M -24.2 M -30.4 M -9.91 M -35.6 M -27.9 M -25.1 M -16.7 M -18.3 M -19.7 M - - - -

Operating Expenses

71.5 M 80.5 M 101 M 88.9 M 91.8 M 96.9 M 35.4 M 26.4 M 24.1 M 25.2 M - - - -

General and Administrative Expenses

36.5 M 41 M 49.6 M 40.1 M 57.9 M 45.3 M 8.83 M 4.9 M 4.14 M 3.26 M - - - -

All numbers in USD currency

Quarterly Income Statement Venus Concept

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

1.86 M 1.46 M 709 K 709 K 709 K 645 K 579 K 5.53 M 5.53 M 5.47 M 5.24 M 5.16 M 4.35 M 4.28 M 4.26 M 64 M 54.1 M 54.1 M 53.7 M 53.6 M 40.5 M 33.3 M 29.8 M 28.7 M 4.88 M 4.78 M 4.78 M 4.77 M 2.33 M 29.1 M 29 M 28.9 M 1.62 M 1.62 M 16.2 M 1.62 M 1.61 M - - - - - - - - - - - - - - - - - - - - - -

Net Income

-22.6 M -11.7 M -12.4 M - -9.29 M -20 M -9.79 M - -8.96 M -7.41 M -9.66 M - -14.6 M -10.6 M -8.62 M - -8.84 M 377 K -9.26 M - -7.24 M -9.59 M -50.2 M - -8.64 M -5.91 M -5.27 M -7.98 M -7.07 M -6.24 M -7.43 M -1.06 M -6.6 M -5.01 M -5.18 M -4.93 M -5.93 M -5.17 M -5.81 M - - - - - - - - - - - - - - - - - - - -

Revenue

13.8 M 15.7 M 13.6 M - 15 M 16.6 M 17.5 M - 17.6 M 20.1 M 20.5 M - 21.5 M 27.3 M 26.4 M - 24.6 M 25.8 M 22.6 M - 20.7 M 17 M 14.5 M - 26.2 M 27.8 M 24.6 M 6.66 M 4.82 M 5.48 M 5 M 5.86 M 4.18 M 5.79 M 5.48 M 5.18 M 3.68 M 3.56 M 3.19 M - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

4.96 M 6.26 M 4.89 M - 5.09 M 4.73 M 5.83 M - 5.43 M 5.86 M 6.83 M - 8.17 M 8.22 M 8.64 M - 7.26 M 7.11 M 7.36 M - 7.18 M 5.1 M 5.23 M - 7.39 M 7.74 M 6.52 M - 2.66 M 2.51 M 3.18 M - 2.47 M 3.49 M 3.09 M - 2.4 M - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

8.82 M 9.43 M 8.76 M - 9.92 M 11.8 M 11.6 M - 12.2 M 14.2 M 13.7 M - 13.4 M 19 M 17.8 M - 17.3 M 18.7 M 15.2 M - 13.5 M 11.9 M 9.28 M - 18.8 M 20.1 M 18.1 M 2.57 M 2.16 M 2.96 M 1.82 M 2.76 M 1.7 M 2.3 M 2.38 M 2.01 M 1.27 M 1.1 M 779 K - - - - - - - - - - - - - - - - - - - -

Operating Income

-9.5 M -9.04 M -9.53 M - -7.16 M -5.6 M -7.76 M - -6.76 M -5.76 M -8.16 M - -11.4 M -7.13 M -7.44 M - -5.39 M 1.53 M -6.84 M - -5.29 M -8.81 M -43.6 M - -6.56 M -3.95 M -1.87 M - -6.44 M -5.17 M -7.04 M - -4.61 M -4.44 M -4.42 M - -5.33 M - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - - - - - - - - - - - - - - - - - - - - - -55 K -8 K -46 K - 12 K -559 K -20 K - -1.47 M -25 K -149 K - 11 K - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-9.4 M -8.95 M -8.58 M - -7.06 M -5.48 M -6.78 M - -6.63 M -5.53 M -7.15 M - -11.2 M -6.82 M -6.34 M - -1.63 M 3.98 M -5.53 M - -1.6 M -6.29 M -42.3 M - -6.34 M -3.79 M -1.54 M - -6.17 M -5.04 M -6.91 M - -4.47 M -4.27 M -4.28 M - -5.18 M - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

18.3 M 18.5 M 18.3 M - 17.1 M 17.4 M 19.4 M - 18.9 M 20 M 21.9 M - 24.8 M 26.2 M 25.2 M - 22.7 M 17.2 M 22.1 M - 18.8 M 20.7 M 52.9 M - 25.3 M 24 M 19.9 M - 8.6 M 8.14 M 8.86 M - 6.31 M 6.75 M 6.81 M - 6.6 M - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

9.65 M 9.43 M 9.74 M - 8.73 M 8.66 M 10.2 M - 10.1 M 9.63 M 11.2 M - 12.4 M 12.9 M 11.5 M - 12 M 7.83 M 12.2 M - 11.3 M 14.6 M 14.2 M - 14.4 M 11.9 M 8.34 M - 2.19 M 1.62 M 2.35 M - 1.14 M 1.48 M 926 K - 1.43 M - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Venus Concept VERO
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Venus Concept plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Abbott Laboratories Abbott Laboratories
ABT
$ 102.87 -0.01 % $ 179 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Penumbra Penumbra
PEN
$ 330.36 - $ 12.9 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Ra Medical Systems Ra Medical Systems
RMED
- 10.0 % $ 610 K usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
STRATA Skin Sciences STRATA Skin Sciences
SSKN
- - $ 6.6 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
ReWalk Robotics Ltd. ReWalk Robotics Ltd.
RWLK
- 7.07 % $ 66.1 M israelIsrael
Aethlon Medical Aethlon Medical
AEMD
$ 2.12 - $ 3.31 M usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 12.03 - $ 1.63 B usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 13.79 - $ 891 M israelIsrael
Align Technology Align Technology
ALGN
$ 170.6 - $ 12.8 B usaUSA
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 3.68 - $ 151 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.42 - $ 43.2 M usaUSA